Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, includ… Read more
Enimmune corporation (6564) - Net Assets
Latest net assets as of June 2025: NT$224.35 Million TWD
Based on the latest financial reports, Enimmune corporation (6564) has net assets worth NT$224.35 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$521.26 Million) and total liabilities (NT$296.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$224.35 Million |
| % of Total Assets | 43.04% |
| Annual Growth Rate | 8.16% |
| 5-Year Change | -22.37% |
| 10-Year Change | N/A |
| Growth Volatility | 41.91 |
Enimmune corporation - Net Assets Trend (2019–2024)
This chart illustrates how Enimmune corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enimmune corporation (2019–2024)
The table below shows the annual net assets of Enimmune corporation from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$479.20 Million | +11.09% |
| 2023-12-31 | NT$431.36 Million | -35.17% |
| 2022-12-31 | NT$665.41 Million | +16.73% |
| 2021-12-31 | NT$570.03 Million | -7.65% |
| 2020-12-31 | NT$617.27 Million | +90.72% |
| 2019-12-31 | NT$323.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enimmune corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39202100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$721.34 Million | 192.84% |
| Other Comprehensive Income | NT$21.90 Million | 5.85% |
| Other Components | NT$140.65 Million | 37.60% |
| Total Equity | NT$374.06 Million | 100.00% |
Enimmune corporation Competitors by Market Cap
The table below lists competitors of Enimmune corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Malaysia Airport Holdings Bhd
KLSE:5014
|
$15.67 Million |
|
Mentice AB
ST:MNTC
|
$15.67 Million |
|
Chang Jia M&E Engineering
TWO:4550
|
$15.67 Million |
|
Leaders Technology Investment Co. Ltd
KQ:019570
|
$15.67 Million |
|
NextNRG Inc.
NASDAQ:NXXT
|
$15.66 Million |
|
Asphere Innovations Public Company Limited
BK:AS
|
$15.65 Million |
|
VPower Group International Holdings Limited
F:2V3
|
$15.64 Million |
|
SAI.TECH Global Corporation
NASDAQ:SAI
|
$15.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enimmune corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 321,952,000 to 374,064,000, a change of 52,112,000 (16.2%).
- Net loss of 157,546,000 reduced equity.
- New share issuances of 202,038,000 increased equity.
- Other comprehensive income increased equity by 24,578,000.
- Other factors decreased equity by 16,958,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-157.55 Million | -42.12% |
| Share Issuances | NT$202.04 Million | +54.01% |
| Other Comprehensive Income | NT$24.58 Million | +6.57% |
| Other Changes | NT$-16.96 Million | -4.53% |
| Total Change | NT$- | 16.19% |
Book Value vs Market Value Analysis
This analysis compares Enimmune corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.29x to 3.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$7.33 | NT$16.80 | x |
| 2020-12-31 | NT$11.52 | NT$16.80 | x |
| 2021-12-31 | NT$9.47 | NT$16.80 | x |
| 2022-12-31 | NT$8.51 | NT$16.80 | x |
| 2023-12-31 | NT$4.89 | NT$16.80 | x |
| 2024-12-31 | NT$5.23 | NT$16.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enimmune corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -394.70%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.93x
- Recent ROE (-42.12%) is below the historical average (-32.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -17.50% | -2913.84% | 0.01x | 1.02x | NT$-89.01 Million |
| 2020 | -12.06% | -325.46% | 0.03x | 1.07x | NT$-136.18 Million |
| 2021 | -8.29% | -43.02% | 0.18x | 1.07x | NT$-104.25 Million |
| 2022 | -45.54% | -131.60% | 0.24x | 1.42x | NT$-302.42 Million |
| 2023 | -69.50% | -514.42% | 0.07x | 1.88x | NT$-255.94 Million |
| 2024 | -42.12% | -394.70% | 0.06x | 1.93x | NT$-194.95 Million |
Industry Comparison
This section compares Enimmune corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enimmune corporation (6564) | NT$224.35 Million | -17.50% | 1.32x | $15.66 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |